Administrative, Regulatory and Cord Blood Bank
行政、监管和脐带血库
基本信息
- 批准号:8555385
- 负责人:
- 金额:$ 11.11万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-09-22 至 2016-08-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAddressAnnual ReportsBiotechnologyBlood BanksBudgetsClinicClinicalClinical ResearchClinical Research ProtocolsClinical TrialsCollaborationsCommitCommunicationConduct Clinical TrialsControlled StudyDataData CollectionDevelopmentDisadvantagedDisputesDoseEngraftmentEnrollmentEnsureEnvironmentEquilibriumFreezingFundingFunding AgencyGoalsGood Clinical PracticeGrantHuman ResourcesImmuneInstitutional Review BoardsInvestigational DrugsLeadershipMedical centerMinorityMonitorPatientsPre-Clinical ModelProceduresProgram Research Project GrantsProtocols documentationPublicationsQuality ControlRecombinant DNARecommendationRegulatory AffairsReport (account)ReportingResearchResearch InfrastructureResearch Peer ReviewResearch PersonnelResearch Project GrantsResearch SupportResource SharingResourcesSafetyServicesSolutionsSourceStem cellsSupervisionTestingTexasTranslatingTranslationsTransplantationUmbilical Cord BloodUmbilical Cord Blood TransplantationUnited States Food and Drug AdministrationUnited States Health Resources and Services AdministrationUnited States National Institutes of HealthUniversity of Texas M D Anderson Cancer CenterValidationVisitdata managementdesignexperienceimprovedmeetingsoperationpre-clinicalpreclinical studyprogramsprotocol developmentquality assurancereconstitutionstem
项目摘要
The goals of this core are to provide all projects and the other cores with centralized leadership, administrative. Cord Blood Bank and clinical research support. The Administrative component will be responsible for integrating all components of the program project grant (PO1) and overseeing progress, so that the research objectives are being met. It will provide assistance to each project and core leader with budgetary issues and will oversee the overall fiscal and budgetary management of the program. This Core will also coordinate oversight of the PO1 by convening meetings of the Internal and External Advisory Boards and implementing their recommendations. The goals of the clinical research component of this core are to provide all projects with clinical trial support in collaboration with Core B and provide an infrastructure of personnel and services that will adequately support such research. Core services will be provided in regulatory affairs, study coordination, quality assurance and control and data safety monitoring. The Regulatory Affairs component collaborates with investigators to develop and submit all required regulatory documents, including submissions to the IRB, IBC, FDA, and NIH/OBA and annual reports. This core has extensive experience with IND submission and currently supports over 45 IND studies. The Quality Control program will ensure that standard operating procedures for protocol development, conduct of clinical trials, data collection and management of clinical trials are accurately defined and being followed. The Quality Assurance program will undertake audits after the first patient is enrolled on a study and then randomly to ensure that the studies are being conducted according to Good Clinical Practices. The MD Anderson Cord Blood Bank is committed to providing cord blood units for pre-clinical peer-reviewed research to advance the field of cord blood transplantation, and will provide all the cord blood units needed to execute the studies proposed in the projects. In this PO1 we have developed strategic approaches to overcome the limitations of cord blood transplantation and will rely on testing potential solutions in carefully designed preclinical models and then translating the results to the clinic.
该核心的目标是为所有项目和其他核心提供集中领导和管理。脐带血库和临床研究支持。行政部门将负责整合计划项目拨款(PO1)的所有组成部分并监督进展,以便实现研究目标。它将向每个项目和核心领导提供预算问题方面的帮助,并将监督该计划的整体财政和预算管理。该核心还将通过召开内部和外部顾问委员会会议并实施其建议来协调 PO1 的监督。该核心临床研究部分的目标是与核心 B 合作为所有项目提供临床试验支持,并提供充分支持此类研究的人员和服务基础设施。将在监管事务、研究协调、质量保证和控制以及数据安全监测方面提供核心服务。监管事务部门与研究人员合作制定并提交所有必需的监管文件,包括向 IRB、IBC、FDA 和 NIH/OBA 提交的文件以及年度报告。该核心在 IND 提交方面拥有丰富的经验,目前支持超过 45 项 IND 研究。质量控制计划将确保准确定义并遵循方案制定、临床试验实施、数据收集和临床试验管理的标准操作程序。质量保证计划将在第一位患者参加研究后进行审核,然后随机进行审核,以确保研究是根据良好临床实践进行的。 MD 安德森脐带血库致力于为临床前同行评审研究提供脐带血单位,以推进脐带血移植领域的发展,并将提供执行项目中提出的研究所需的所有脐带血单位。在本次 PO1 中,我们制定了克服脐带血移植局限性的战略方法,并将依靠在精心设计的临床前模型中测试潜在的解决方案,然后将结果转化为临床。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Elizabeth J Shpall其他文献
NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model
NPRL2 基因治疗在人源化小鼠模型中诱导 KRAS/STK11 突变型抗 PD1 耐药转移性非小细胞肺癌 (NSCLC) 有效的抗肿瘤免疫
- DOI:
10.1101/2024.03.26.586829 - 发表时间:
2024-03-28 - 期刊:
- 影响因子:0
- 作者:
Ismail M. Meraz;Mourad Majidi;R. Song;Meng Feng;Lihui Gao;Qi Wang;Jing Wang;Elizabeth J Shpall;Jack A Roth - 通讯作者:
Jack A Roth
Elizabeth J Shpall的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Elizabeth J Shpall', 18)}}的其他基金
SPORE University of Texas M. D. Anderson Cancer Center-Leukemia
SPORE 德克萨斯大学 MD 安德森癌症中心 - 白血病
- 批准号:
10911713 - 财政年份:2023
- 资助金额:
$ 11.11万 - 项目类别:
Cord Blood Graft Engineering to Improve Engraftment and Reduce GVHD
脐带血移植工程可改善移植并减少 GVHD
- 批准号:
10478151 - 财政年份:2011
- 资助金额:
$ 11.11万 - 项目类别:
Cord Blood Expansion and Homing to Improve Engraftment
脐带血扩张和归巢以改善植入
- 批准号:
9340308 - 财政年份:2011
- 资助金额:
$ 11.11万 - 项目类别:
Cord Blood Expansion and Homing to Improve Engraftment
脐带血扩张和归巢以改善植入
- 批准号:
8555381 - 财政年份:2011
- 资助金额:
$ 11.11万 - 项目类别:
Cord Blood Graft Engineering to Improve Engraftment and Reduce GVHD
脐带血移植工程可改善移植并减少 GVHD
- 批准号:
10247041 - 财政年份:2011
- 资助金额:
$ 11.11万 - 项目类别:
Good Manufacturing Practice (GMP) and Immune Assessment Core
良好生产规范 (GMP) 和免疫评估核心
- 批准号:
8000169 - 财政年份:2010
- 资助金额:
$ 11.11万 - 项目类别:
DETECTION OF MALIGNANT CELLS IN MARROW & PBPC FRACTIONS
骨髓中恶性细胞的检测
- 批准号:
2863385 - 财政年份:1998
- 资助金额:
$ 11.11万 - 项目类别:
相似国自然基金
本体驱动的地址数据空间语义建模与地址匹配方法
- 批准号:41901325
- 批准年份:2019
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
时空序列驱动的神经形态视觉目标识别算法研究
- 批准号:61906126
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
针对内存攻击对象的内存安全防御技术研究
- 批准号:61802432
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
- 批准号:61802133
- 批准年份:2018
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
- 批准号:61872252
- 批准年份:2018
- 资助金额:64.0 万元
- 项目类别:面上项目
相似海外基金
Racial/Ethnic Disparities in Ovarian Cancer Treatment and Survival: An Integrative Approach
卵巢癌治疗和生存的种族/民族差异:综合方法
- 批准号:
10186716 - 财政年份:2020
- 资助金额:
$ 11.11万 - 项目类别:
Racial/Ethnic Disparities in Ovarian Cancer Treatment and Survival: An Integrative Approach
卵巢癌治疗和生存的种族/民族差异:综合方法
- 批准号:
10671466 - 财政年份:2020
- 资助金额:
$ 11.11万 - 项目类别:
Racial/Ethnic Disparities in Ovarian Cancer Treatment and Survival: An Integrative Approach
卵巢癌治疗和生存的种族/民族差异:综合方法
- 批准号:
10737847 - 财政年份:2020
- 资助金额:
$ 11.11万 - 项目类别:
Racial/Ethnic Disparities in Ovarian Cancer Treatment and Survival: An Integrative Approach
卵巢癌治疗和生存的种族/民族差异:综合方法
- 批准号:
10450747 - 财政年份:2020
- 资助金额:
$ 11.11万 - 项目类别: